Zita‐Rose Manjaly Thomas

Author

University of Oxford ORCID

Also Known As

Z Thomas, Z. M. Thomas, Zack Thomas, Zita-Rose Manjaly Thomas, Zita‐Rose Manjaly Thomas

Publications

685

Citations

H-Index

Concepts

All Affiliations

University of Oxford Jenner Institute University of Birmingham Aeras London School of Hygiene & Tropical Medicine

About

Zita‐Rose Manjaly Thomas is an author at University of Oxford specializing in t cell immunity, medicine, and immune regulation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	24
2	Immunology	1	1	24
3	Immune Function	1	1	24
4	Immune Regulation	1	1	24
5	Immune Surveillance	1	1	24

Zita‐Rose Manjaly Thomas

Publications

635

Citations

H-Index

Page 1

	Year	Citations
Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial Iman Satti, Joel N. Meyer, Stephanie A. Harris, The Lancet Infectious Diseases	2014	175
Fiction, Falsehoods, and Few Facts: Cross-Sectional Study on the Content-Related Quality of Atopic Eczema-Related Videos on YouTube Simon M. Mueller, Valentina N. S. Hongler, Pierre Jungo, Journal of Medical Internet Research	2020	129
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults Morven Wilkie, Iman Satti, Alice Minhinnick, Vaccine	2019	88
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial Zita‐Rose Manjaly Thomas, Iman Satti, Julia L. Marshall, PLoS Medicine	2019	66
Cytomegalovirus infection is a risk factor for tuberculosis disease in infants Julius Müller, Rachel Tanner, Magali Matsumiya, JCI Insight	2019	60
A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults Alice Minhinnick, Iman Satti, Stephanie A. Harris, Vaccine	2016	42
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults Sharon R. Sheehan, Stephanie A. Harris, Iman Satti, PLoS ONE	2015	40
Cytomegalovirus infection is a risk factor for TB disease in Infants Julius Müller, Rachel Tanner, Magali Matsumiya, Immune ActivationAdaptive Immune SystemTuberculosis PreventionImmunologyImmune Regulation	2017	24
Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A Stephanie A. Harris, Iman Satti, Magali Matsumiya, Clinical and Vaccine Immunology	2014	11

Page 1